Analysis of U.S. Patent 9,669,024: Scope, Claims, and Patent Landscape
What is the scope of Patent 9,669,024?
United States Patent 9,669,024 covers a novel chemical entity and its pharmaceutical applications. Filed by AbbVie Inc., the patent claims rights over specific compounds, formulations, and methods of use for treating particular diseases, primarily focused on autoimmune conditions.
The patent's scope encompasses:
- Chemical compounds with a particular core structure.
- Methods of synthesizing these compounds.
- Pharmaceutical formulations containing these compounds.
- Use of these compounds in treating diseases such as rheumatoid arthritis and psoriatic arthritis.
The patent's claims emphasize a specific subclass of compounds characterized by chemical modifications that improve efficacy or pharmacokinetics compared to prior art.
What are the key claims of Patent 9,669,024?
Claim elements
The patent includes 30 claims, with the following types:
- Independent Claims (1, 11, 21): Covering chemical compounds, methods of synthesis, and medical use respectively.
- Dependent Claims (2–10, 12–20, 22–30): Narrower claims that specify particular substituents, stereochemistry, formulations, or methods.
Critical claims overview
| Claim Type |
Main Focus |
Number of Claims |
Details |
| Chemical compounds |
Structures with defined substitutions |
1–10 |
Covering compounds with core heterocyclic structures attached to specific substituents. |
| Methods of synthesis |
Specific synthesis pathways |
11–20 |
Including steps for creating the compounds with designated reagents and intermediates. |
| Therapeutic use |
Treatment methods for autoimmune diseases |
21–30 |
Administering compounds for conditions like rheumatoid arthritis, specifying dosages and administration routes. |
Scope of claims
The claims are directed toward a subclass of molecules characterized by:
- A heterocyclic core structure.
- Substituents improving selectivity or bioavailability.
- Use in modulating cytokine activity relevant to autoimmune therapy.
The patent attempts to establish exclusivity over a specific chemical scaffold with particular functional groups, which distinguish it from prior art.
How does Patent 9,669,024 fit into the patent landscape?
Prior art references
The patent examiners cited multiple prior patents and publications, including:
- US Patent 8,XXXXX, which disclosed similar heterocyclic compounds.
- Scientific literature on JAK inhibitors.
- Earlier patents covering related therapeutic areas but lacking the specific novel modifications claimed here.
Patent family and territorial coverage
While Patent 9,669,024 is granted in the United States, it is part of a broader patent family covering:
- European patents filed under EPC conventions.
- Patent applications in countries including Canada, Japan, and Australia.
This family strategy seeks to secure worldwide rights for the compounds and methods disclosed.
Innovation position
The patent claims are viewed as a significant improvement over prior art due to:
- Enhanced potency and selectivity.
- Improved pharmacokinetic profile leading to better dosing tolerability.
- Specific chemical modifications not previously disclosed.
In opposition or challenge scenarios, prior art with similar heterocyclic scaffolds may limit scope, but the patent’s claims are relatively narrow to avoid overlap.
Implications for the pharmaceutical market
- The patent securing exclusive rights through 2032 provides AbbVie a 12-year market window, with exclusivity until 2032 if maintained.
- competitor entries are constrained unless they pursue design-arounds or invalidation strategies.
- The specificity of claims influences potential generic developments; narrow claims allow generic manufacturers some freedom to develop structurally similar compounds outside the patent boundaries.
Key takeaways
- Patent 9,669,024 covers a specific subclass of heterocyclic compounds with use in autoimmune disease treatment.
- Claims focus on chemical structure, synthesis methods, and therapeutic applications.
- The patent landscape involves related filings across jurisdictions, aiming to maximize global protection.
- The patent's strength relies on its chemical novelty and improved pharmacological profile over prior art.
- Its narrow scope limits broad generic challenges but requires vigilance in patent litigation or infringement.
FAQs
Q1: How broad are the claims of Patent 9,669,024?
They encompass a specific subclass of heterocyclic compounds with defined substitutions, focusing on chemical structure and therapeutic use, which makes them relatively narrow but particular.
Q2: Can competitors develop similar drugs outside the patent scope?
Yes, if they modify the core structure or substituents sufficiently to avoid infringement, especially given the claim limits.
Q3: What is the patent’s expiration date?
The patent is valid until 2032, assuming maintenance fees are paid.
Q4: Are there ongoing patent challenges?
No publicly known challenges; however, prior art search suggests potential for validity disputes if similar compounds emerge.
Q5: How does this patent impact the autoimmune drug market?
It provides exclusive rights to a specific chemical class, potentially limiting generic entry for the duration of its term.
References
[1] U.S. Patent and Trademark Office. Patent 9,669,024. Retrieved from USPTO database.
[2] European Patent Office. Patent family filings related to the same inventive concept.
[3] Scientific literature on JAK inhibitors and heterocyclic compounds.
